Raltegravir in Pregnancy

PANNA Trial
**Study Design: PANNA Network Study**

- **Background**: Open-label, nonrandomized, phase 4 trial evaluating the effects of pregnancy on the pharmacokinetics of raltegravir and its safety and efficacy in pregnant women with HIV.

- **Inclusion Criteria (n = 52)**
  - Age ≥18 years
  - Taking raltegravir 400 mg BID ≥2 weeks prior to initial assessment in 3rd trimester of pregnancy
  - On raltegravir for optimization/intensification of 3-drug regimen or as alternative to another ART medication

- **Treatment Arm**
  - Raltegravir + background antiretroviral regimen

Raltegravir in Pregnancy
PANNA: Results

Virologic Suppression at Delivery

Raltegravir in Pregnancy
PANNA: Results

Pregnancy Outcomes

Conclusions: “Raltegravir was well tolerated during pregnancy. The pharmacokinetics of raltegravir showed extensive variability. The observed mean decrease in exposure to raltegravir during third trimester compared to postpartum is not considered to be of clinical importance. Raltegravir can be used in standard dosages in HIV-infected pregnant women.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*